Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat

Sanati, Mehdi; Afshari, Amir R.; Ahmadi, Seyed Sajad; Kesharwani, Prashant; Sahebkar, Amirhossein

doi:10.1016/j.bbadis.2023.166720

Cited by 8 publications

(1 citation statement)

References 229 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their main characteristic is their ability to recognize molecule targets based on their three-dimensional (3D) structures [12]. They have proven to be invaluable tools in the field of drug discovery, enabling the identification and characterization of novel therapeutic targets [12,13]. Aptamers can be utilized to explore the molecular pathways involved in cancer development and progression, shedding light on key biomarkers and signaling mechanisms [14].…”

Section: Introductionmentioning

confidence: 99%

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Szymanowski,

Szymanowska,

Bielawska

et al. 2023

Cancers

View full text Add to dashboard Cite

Ovarian cancer (OC) is the most common lethal gynecologic cause of death in women worldwide, with a high mortality rate and increasing incidence. Despite advancements in the treatment, most OC patients still die from their disease due to late-stage diagnosis, the lack of effective diagnostic methods, and relapses. Aptamers, synthetic, short single-stranded oligonucleotides, have emerged as promising anticancer therapeutics. Their ability to selectively bind to target molecules, including cancer-related proteins and receptors, has revolutionized drug discovery and biomarker identification. Aptamers offer unique insights into the molecular pathways involved in cancer development and progression. Moreover, they show immense potential as drug delivery systems, enabling targeted delivery of therapeutic agents to cancer cells while minimizing off-target effects and reducing systemic toxicity. In the context of OC, the integration of aptamers with non-coding RNAs (ncRNAs) presents an opportunity for precise and efficient gene targeting. Additionally, the conjugation of aptamers with nanoparticles allows for accurate and targeted delivery of ncRNAs to specific cells, tissues, or organs. In this review, we will summarize the potential use and challenges associated with the use of aptamers alone or aptamer–ncRNA conjugates, nanoparticles, and multivalent aptamer-based therapeutics for the treatment of OC.

show abstract